Scientists spent the next three decades teasing apart the underpinnings of viral biology to create a new generation of vectors. Among these, lentivirus-based vectors, derived from the HIV-1 ...

However, it is often difficult for scientists to ramp up the generation of these vectors to meet their ... from Thermo Fisher Scientific to learn how scientists have used their lentiviral production ...

Lentiviruses have the unique ability amongst retroviruses of being able to infect non-cycling cells. Vectors derived from lentiviruses have provided a huge advancement in technology and seemingly ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Vyriad's targeted lentiviral vector platform provides T ... Inc. Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered ...